Results for tag: "Down Syndrome Drug"

The Down Syndrome Drug market is a subset of the Pharmaceuticals industry that focuses on the development and sale of drugs to treat Down Syndrome. Down Syndrome is a genetic disorder caused by the presence of an extra chromosome, and is associated with a range of physical and cognitive disabilities. The market for Down Syndrome drugs is relatively small, but is growing as more treatments become available. The market for Down Syndrome drugs is largely driven by the need to improve the quality of life for those affected by the disorder. As such, the focus of the market is on treatments that can improve physical and cognitive functioning, as well as those that can reduce the risk of associated medical conditions. Some of the companies in the Down Syndrome Drug market include AbbVie, Biogen, GlaxoSmithKline, Novartis, Pfizer, and Sanofi. Show Less Read more